1.	Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: not specified Sponsor: NCI, Other Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, NCT01231412
2.	Bortezomib and Sorafenib Tosylate in Patients With Newly Diagnosed Acute Myeloid Leukemia With or Without Mutations Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Under 30 Sponsor: NCI Protocol IDs: NCI-2011-02670, AAML1031, U10CA098543, COG-AAML1031, NCT01371981
3.	Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Phase: Phase III Type: Treatment Status: Active Age: 3 to 70 Sponsor: Other Protocol IDs: 2011-0628, NCT01471444
4.	Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 15 to 60 Sponsor: NCI Protocol IDs: NCI-2013-00490, S1203, SWOG-S1203, U10CA032102, NCT01802333
5.	Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: Any age Sponsor: NCI, Other Protocol IDs: 2230.00, NCI-2010-00106, P01CA078902, FHCRC-2230.00, IR-6771, NCT00789776
6.	5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) Phase: Phase II, Phase I Type: Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: 2009-0467, NCT01038635
7.	Improving Blood Stem Cell Collection and Transplant Procedures Phase: Phase II, Phase I Type: Treatment Status: Active Age: 3 to 79 Sponsor: NHLBI Protocol IDs: 120028, 12-H-0028, NCT01517035
8.	Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Not specified Sponsor: NCI, Other Protocol IDs: 2498.00, NCI-2011-03362, P01CA018029, NCT01640301
9.	Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Treatment Status: Active Age: 65 and under Sponsor: NCI Protocol IDs: CPMC-IRB-AAAA5571, CPMC-CAMP-016, NCI-G00-1891, NCT00008216
10.	Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant For Hematologic Cancer Phase: Phase II Type: Supportive care, Treatment Status: Active Age: Under 75 Sponsor: NCI, Other Protocol IDs: 1898.00, NCI-2010-00267, P01HL036444, P01CA078902, FHCRC-1898.00, 5788, NCT00089011
11.	HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies Phase: Phase II Type: Treatment Status: Active Age: Under 24 months Sponsor: Other Protocol IDs: INF-T2, NCT00145626
12.	Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Phase: Phase II Type: Supportive care, Treatment Status: Active Age: Under 65 Sponsor: Other Protocol IDs: 08-008, NCT00629798
13.	Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 75 and under Sponsor: NCI, Other Protocol IDs: 2212.00, NCI-2009-01244, P01CA018029, U19AI096111, NCT00968630
14.	CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant Phase: Phase II Type: Treatment Status: Active Age: 0 to 26 Sponsor: Other Protocol IDs: L 10,321, NYMC 525, NCT01049854
15.	Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2 Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: 2010-0284, NCT01200485
16.	Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant Phase: Phase II Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: Not specified Sponsor: NCI, Other Protocol IDs: 2206.00, NCI-2010-02222, P01CA018029, NCT01251575
17.	Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: UCBT01, NCT01328496
18.	Bulk Versus Fractionated Stem Cell Infusions in Patients With Hematologic Malignancies Undergoing Stem Cell Transplantation Phase: Phase II Type: Treatment Status: Active Age: Under 75 Sponsor: Other Protocol IDs: 12-016, NCT01596257
19.	Peripheral Blood Stem Cell Transplantation Using the CliniMACS Device Phase: Phase II Type: Treatment Status: Active Age: 22 and under Sponsor: Other Protocol IDs: CHOP 07/216, NCT01071226
20.	KIR Mismatched Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy Phase: Phase II Type: Treatment Status: Active Age: 21 and over Sponsor: Other Protocol IDs: HAPNK1, NCT01807611
21.	Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies Phase: Phase I Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: 2009-0521, NCT01015222
22.	Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies Phase: Phase I Type: Treatment Status: Active Age: any age Sponsor: Other Protocol IDs: 2009-0855, NCT01113476
23.	Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia Phase: Phase I Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: Not specified Sponsor: NCI, Other Protocol IDs: 9L-11-8, NCI-2013-00447, NCT01801046
24.	Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Phase: No phase specified Type: Treatment Status: Active Age: Over 6 Sponsor: NCI, Other Protocol IDs: 04199, P30CA033572, CHNMC-04199, CDR0000570241, NCI-2010-00355, NCT00544466